ciltacabtagene autoleucel

all catalysts(0)

nothing on the calendar yet

News(10)

• Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
  Plus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…
  endpoints · 8d ago
• J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
  Ten patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.
  biospace · 8d ago
• Legend names new CEO as Carvykti competition grows; Vertex makes a flurry of moves
  → Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act. The company’s shares {$LEGN} are down 50% ...
  endpoints · 15d ago
• Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
  After former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…
  fiercebiotech · 16d ago
• Unlocking cell surface protein research with site-specific labeling
  Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
  biospace · 20d ago
• The hidden scale-out problem behind CAR-T’s growth
  CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In vivo" production techniques could be one solution.
  biopharma_dive · 1mo ago
• Chutes & Ladders—Former Legend CEO lands at K2
  Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…
  fiercebiotech · 1mo ago
• Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
  Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.
  biopharma_dive · 1mo ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 2mo ago
• Chutes & Ladders—Legend CEO departs without successor in place
  Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
  fiercebiotech · 2mo ago